NYSE : NVO

Novo Nordisk A/S

$51.58 USD

$0.62 (1.22%)

Volume
8.13M
Average Volume
12.81M
Market Capitalization
$229.21B
P/E Ratio
12.15
Dividend Yield
3.51%
Price Target
$45.00
Year High
$64.16
Year Low
$35.12
Day High
—
Day Low
—
Payout Ratio
$0.42
Current Ratio
$0.79
Company Overview

NYSE

Maziar Mike Doustdar

Drug Manufacturers - General

Healthcare

NVO

77406

DK

USD

https://www.novonordisk.com

45 44 44 88 88

670100205

0000353278

Liquidity Metrics

0.72

0.79

0.56

0.09

0.42

Sales & Valuation

$309.06B

4.52

7.30

47.74

6.98

Profitability

$23.03

$102.43B

37.20%

47.49%

66.36%

21.81%

P/E Metrics

12.15

0.73

0.73

Analyst Price Target & Rating

$45.00

$45.00

$45.00

Buy

4/5

39 Analysts

14.62%

Financial Health Scores

4.47

5/9

-$47.84B

$559.22B

$356.16B

$164.14B

Key Metrics (TTM)

$1.61T

4.91

9.05

0.79

66.36%

32.20%

8.22%

2.09%

$168.03

-396 days

Company Executives
Name Title
Hong Chow Executive Vice President of Product & Portfolio Strategy and Member of Management Board
Tania Sabroe EVP of People, Organisation and Corporate Affairs & Member of Management Board
Thilde Hummel Bogebjerg Executive VP of Enterprise IT & Quality and Member of Management Board
Emil Kongshøj Larsen EVP of International Operations & Member of Management Board
Jamey Millar Executive Vice President of US Operations & Member of Management Board
John F. Kuckelman SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board
Karsten Munk Knudsen Executive Vice President, Chief Financial Officer & Member of the Management Board
Maziar Mike Doustdar President, Chief Executive Officer & Member of the Management Board
Elin Jager SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board
Martin Holst Lange EVP of R&D, Chief Scientific Officer and Member of the Management Board
Poll Results

No votes yet today — be the first to share your view!

About Novo Nordisk A/S (NYSE:NVO) Stock

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its cor ... e pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold

2026-07-29 16:34:00

They may profit from the rapidly growing GLP-1 market in very different ways.

How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?

2026-07-29 12:41:11

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

2026-07-29 09:11:19

Novo Nordisk shareholders allege the company misled investors about a key clinical trial for its next-generation weight-loss drug CagriSema. A U.S. judge on Tuesday allowed parts of that lawsuit to move forward.

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

2026-07-29 07:30:00

Amgen wants a slice of the weight loss drug market. Its candidate for capturing that market share might not be up to the task.

Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing

2026-07-28 18:45:47

Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.

Novo Nordisk must face US shareholder lawsuit over CagriSema clinical trial

2026-07-28 13:00:38

A U.S. judge said ​on Tuesday that Novo Nordisk ‌must face part of a lawsuit accusing it of defrauding shareholders about ​a clinical trial for ​its weight loss and diabetes ⁠treatment CagriSema.

Where Will Novo Nordisk Stock Be in 3 Years?

2026-07-28 08:51:00

Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.

Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy

2026-07-27 09:41:04

Novo Nordisk (NVO) is rated a Modest Buy with a raised price target of $80, driven by oral Wegovy's rapid market adoption. Oral Wegovy has achieved over 3 million prescriptions in five months, with 80% from GLP-1–naïve patients, expanding the addressable market. Sensitivity analysis suggests a base case wherein oral Wegovy could generate $12–$15 billion in annual gross profit under realistic assumptions.

Frequently Asked Questions

What is the current Novo Nordisk A/S (NVO) stock price?

Novo Nordisk A/S(NYSE:NVO) stock price is $51.58 in the last trading session. During the trading session, NVO stock reached the peak price of $64.16 while $35.12 was the lowest point it dropped to. The percentage change in NVO stock occurred in the recent session was 1.22% while the dollar amount for the price change in NVO stock was $0.62.

NVO's industry and sector of operation?

The NYSE listed NVO is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of NVO?

Hong Chow | Executive Vice President of Product & Portfolio Strategy and Member of Management Board
Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board
Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board
Emil Kongshøj Larsen | EVP of International Operations & Member of Management Board
Jamey Millar | Executive Vice President of US Operations & Member of Management Board

How many employees does NVO have?

Number of NVO employees currently stands at 77406. NVO operates from Novo Alle 1, Bagsvaerd, CR 2880, DK.

Link for NVO official website?

Official Website of NVO is: https://www.novonordisk.com

How do I contact NVO?

NVO could be contacted at phone #45 44 44 88 88 and can also be accessed through its website. NVO operates from Novo Alle 1, Bagsvaerd, CR 2880, DK.

How many shares of NVO are traded daily?

The average number of NVO shares traded daily for last 3 months was 12.81M.

What is the market cap of NVO currently?

The market value of NVO currently stands at $229.21B with its latest stock price at $51.58